Literature DB >> 18026102

Cystatin C modulates cerebral beta-amyloidosis.

Stephan A Kaeser1, Martin C Herzig, Janaky Coomaraswamy, Ellen Kilger, Maj-Linda Selenica, David T Winkler, Matthias Staufenbiel, Efrat Levy, Anders Grubb, Mathias Jucker.   

Abstract

The CST3 Thr25 allele of CST3, which encodes cystatin C, leads to reduced cystatin C secretion and conveys susceptibility to Alzheimer's disease. Here we show that overexpression of human cystatin C in brains of APP-transgenic mice reduces cerebral amyloid-beta deposition and that cystatin C binds amyloid-beta and inhibits its fibril formation. Our results suggest that cystatin C concentrations modulate cerebral amyloidosis risk and provide an opportunity for genetic risk assessment and therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18026102     DOI: 10.1038/ng.2007.23

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  72 in total

1.  Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology.

Authors:  Claudia Ditzen; Ning Tang; Archana M Jastorff; Larysa Teplytska; Alexander Yassouridis; Giuseppina Maccarrone; Manfred Uhr; Thomas Bronisch; Christine A Miller; Florian Holsboer; Christoph W Turck
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

2.  Cystatin C and cognitive impairment 10 years later in older women.

Authors:  Yelena Slinin; Katherine W Peters; Areef Ishani; Kristine Yaffe; Howard A Fink; Katie L Stone; Michael Steffes; Kristine E Ensrud
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-11-01       Impact factor: 6.053

3.  Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.

Authors:  Jose Morales-Corraliza; Stephen D Schmidt; Matthew J Mazzella; Jason D Berger; Donald A Wilson; Daniel W Wesson; Mathias Jucker; Efrat Levy; Ralph A Nixon; Paul M Mathews
Journal:  Neurobiol Aging       Date:  2012-05-18       Impact factor: 4.673

4.  Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.

Authors:  Henrik Ryberg; Jiyan An; Samuel Darko; Jonathan Llyle Lustgarten; Matt Jaffa; Vanathi Gopalakrishnan; David Lacomis; Merit Cudkowicz; Robert Bowser
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

Review 5.  Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.

Authors:  Daniel W Wesson; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

Review 6.  Association of cystatin C with adverse outcomes.

Authors:  Magdalena Madero; Mark J Sarnak
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-05       Impact factor: 2.894

7.  Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease.

Authors:  Binggui Sun; Yungui Zhou; Brian Halabisky; Iris Lo; Seo-Hyun Cho; Sarah Mueller-Steiner; Nino Devidze; Xin Wang; Anders Grubb; Li Gan
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

8.  Cystatin C is released in association with exosomes: a new tool of neuronal communication which is unbalanced in Alzheimer's disease.

Authors:  Roberta Ghidoni; Anna Paterlini; Valentina Albertini; Michela Glionna; Eugenio Monti; Luisa Schiaffonati; Luisa Benussi; Efrat Levy; Giuliano Binetti
Journal:  Neurobiol Aging       Date:  2009-09-20       Impact factor: 4.673

9.  Steered molecular dynamics simulation of the binding of the β2 and β3 regions in domain-swapped human cystatin C dimer.

Authors:  Jianwei He; Linan Xu; Shuo Zhang; Jing Guan; Manli Shen; Hui Li; Youtao Song
Journal:  J Mol Model       Date:  2012-10-12       Impact factor: 1.810

10.  Serum cystatin C and the risk of Alzheimer disease in elderly men.

Authors:  J Sundelöf; J Arnlöv; E Ingelsson; J Sundström; S Basu; B Zethelius; A Larsson; M C Irizarry; V Giedraitis; E Rönnemaa; M Degerman-Gunnarsson; B T Hyman; H Basun; L Kilander; L Lannfelt
Journal:  Neurology       Date:  2008-09-30       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.